Skip to main content
. Author manuscript; available in PMC: 2015 Jul 15.
Published in final edited form as: Int J Cancer. 2015 Jan 13;137(2):385–394. doi: 10.1002/ijc.29394

Figure 1.

Figure 1

sAxl levels in HCC patients. (a) sAxl serum concentrations in healthy controls (n = 125), cirrhotic controls (n = 30) and patient samples with HCC (n = 311) or very early HCC (BCLC 0; n = 26), early HCC (BCLC A; n = 78) or advanced HCC (BCLC > A; n = 200) as assessed by ELISA. Horizontal bars indicate median levels with interquartile ranges. (b) Correlation of sAxl release with other cancer types. HCC, hepatocellular carcinoma; CRC, colorectal carcinoma.